Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Summary

This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.

Timeline

Start

1999-04

Primary completion

2013-09

Completion

2013-09

Drugs

Indications